Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders

Anxiety Disorders Clinical Trial

— ROP  

Official title:

Effects of Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00447733
• Other study ID #: 78i068
• Secondary ID: NFR175394/V50
• Status: Completed
• Phase: N/A
• First received: March 14, 2007
• Last updated: March 23, 2012
• Start date: March 2007
• Est. completion date: December 2010

Study information

• Verified date: March 2012
• Source: University of Oslo
• Contact: n/a
• Is FDA regulated: No
• Health authority: Norway: Norwegian Social Science Data Services
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Integrated Treatment is effective in the treatment of anxiety and/or depression with co-occurring substance use disorders.

Description:

Patients with mental disorders and co-occuring substance use disorders are characterized by high suicide rates, high treatment drop-out rates and long-lasting interpersonal, work, school, health and legal problems. Because mental disorders and substance use disorders co-exist and interact, it may be important to provide a treatment that addresses the substance misuse and mental health problems in an integrated and comprehensive way. Additionally, the health services for patients with mental health and substance use disorders are usually provided by different services and health professionals that rarely cooperate or have qualifications on both kinds of disorders. This also calls for an integration of the services on an organizational level. This approach of integrating services and treatment approaches for both diseases in a comprehensive way is called Integrated Treatment. Several studies have shown that Integrated Treatment is effective in treating the comorbidity of severe mental illness and substance use disorders. The over-all aim of this study is to evaluate the effects of evidence-based Integrated Treatment in anxiety and/or depression with co-occurring substance use disorders. The effects of the treatment will be assesses on changes in substance use and psychopathology.

Comparison: patients receiving treatment-as-usual or non-manualized treatment at general mental health outpatients clinics.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 76
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• clinical diagnosis of substance use disorder

• clinical diagnosis of anxiety disorders

• clinical diagnosis of nonpsychotic mood disorders

• written consent

• planning to live in the catchment area during the treatment

Exclusion Criteria:

• schizophrenia spectrum disorders

• other psychotic disorders

• mental retardation

• nicotine abuse/dependency only

• prescription drug abuse/dependency only

• planning to move out of the catchment area during the study

• not able to read or write Norwegian

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anxiety Disorders
• Disease
• Mental Disorders
• Mood Disorders
• Psychotic Disorders
• Substance Use Disorders
• Substance-Related Disorders

Intervention

Behavioral:
• Integrated mental health and substance use treatment
Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
• Treatment as usual
Non-standardized psychiatric outpatient treatment

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University of Oslo	SINTEF Health Research

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Symptom Check List 90 (SCL90-r), The Alcohol Use Disorder Identification Test (AUDIT), The Drug Use Disorder Identification Test (DUDIT).	We use the SCL-90r to measure symptoms in regard to anxiety, depression and the General Severity Index.; We use the AUDIT and the DUDIT to measure changes in the use of alcohol and illegal drugs respectively.	Change during 6 and 12 months follow-up	No
Secondary	The Addiction Severity Index (Europ ASI)	The Addiction Severity Index (Europ ASI) is used to assess changes in the use of alcohol and illegal substances during the course of the trial.	Change during 6 and 12 months follow up	No